Cannabidiol/tetrahydrocannabinol - PhytoTech Therapeutics

Drug Profile

Cannabidiol/tetrahydrocannabinol - PhytoTech Therapeutics

Alternative Names: PNL-THC:CBD; PTL 201

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator MMJ PhytoTech
  • Class Analgesics; Antiemetics; Antispasmodics; Anxiolytics; Appetite stimulants; Cannabinoids; Muscle relaxants; Neuroprotectants; Phytotherapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 03 Jan 2017 Preclinical trials in Multiple sclerosis in Israel (PO) before January 2017 (MMJ PhytoTech pipeline, January 2016)
  • 25 Dec 2016 PhytoTech Therapeutics plans a phase II trial for Multiple sclerosis in Israel (NCT03005119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top